Tango Therapeutics logo

Tango TherapeuticsNASDAQ: TNGX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

03 September 2020

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$551.79 M
-58%vs. 3y high
66%vs. sector
-vs. 3y high
-vs. sector
-58%vs. 3y high
60%vs. sector
-64%vs. 3y high
79%vs. sector

Price

after hours | Fri, 01 Nov 2024 20:20:00 GMT
$5.15-$0.55(-9.65%)

Dividend

No data over the past 3 years
$19.88 M$7.81 M
$19.88 M-$25.55 M

Analysts recommendations

Institutional Ownership

TNGX Latest News

Tango Therapeutics (TNGX) Surges 6.7%: Is This an Indication of Further Gains?
zacks.com23 July 2024 Sentiment: POSITIVE

Tango Therapeutics (TNGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Tango Therapeutics (TNGX) Moves 10.3% Higher: Will This Strength Last?
zacks.com14 June 2024 Sentiment: POSITIVE

Tango Therapeutics (TNGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program
prnewswire.com23 May 2024 Sentiment: NEGATIVE

STOCKHOLM , May 23, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Medivir's licensee, Tango Therapeutics (NASDAQ: TNGX; Tango), has announced that the phase 1/2 clinical trial of TNG348, a novel USP1 inhibitor, is being terminated due to toxicity observed in the initial study cohorts.  TNG348 is a novel USP1 (ubiquitin-specific protease 1) inhibitor, for the treatment of BRCA1/2-mutant and other homologous recombination deficiency (HRD)+ cancers, and has been developed by Tango from the preclinical USP1 program licensed from Medivir in 2020.

Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research18 March 2024 Sentiment: NEGATIVE

Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.33 per share a year ago.

Wall Street Analysts Predict an 110.53% Upside in Tango Therapeutics, Inc. (TNGX): Here's What You Should Know
Zacks Investment Research08 December 2023 Sentiment: POSITIVE

The average of price targets set by Wall Street analysts indicates a potential upside of 110.5% in Tango Therapeutics, Inc. (TNGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Circling Bank On Tango Therapeutics
Seeking Alpha23 October 2023 Sentiment: POSITIVE

We are circling back on clinical stage developmental concern Tango Therapeutics, Inc. for the first time since November 2022. The company recently raised capital to fund all operations well into 2027, and a beneficial owner/director just added just over $2.4 million of new shares to their stake. An updated analysis on Tango Therapeutics follows in the paragraphs below.

Tango Therapeutics (TNGX) Rises 20% in a Month: Here's Why
Zacks Investment Research10 October 2023 Sentiment: POSITIVE

The upside in Tango's (TNGX) shares can be attributed to the company's progress with its pipeline candidates. A recent acquisition offer for a biotech making similar drugs also bolstered this surge.

Why Shares of Tango Therapeutics Are Dropping Monday
The Motley Fool09 October 2023 Sentiment: NEUTRAL

Tango Therapeutics is a clinical-stage biotech. The company has five programs in its pipeline that are focused on fighting various cancers.

What Makes Tango Therapeutics, Inc. (TNGX) a Good Fit for 'Trend Investing'
Zacks Investment Research09 October 2023 Sentiment: POSITIVE

Tango Therapeutics, Inc. (TNGX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Why Shares of Tango Therapeutics Climbed This Week
The Motley Fool14 September 2023 Sentiment: POSITIVE

Tango said it has $310.7 million in cash, enough to fund operations into 2026. The company has several early-stage trials.

What type of business is Tango Therapeutics?

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

What sector is Tango Therapeutics in?

Tango Therapeutics is in the Healthcare sector

What industry is Tango Therapeutics in?

Tango Therapeutics is in the Biotechnology industry

What country is Tango Therapeutics from?

Tango Therapeutics is headquartered in United States

When did Tango Therapeutics go public?

Tango Therapeutics initial public offering (IPO) was on 03 September 2020

What is Tango Therapeutics website?

https://www.tangotx.com

Is Tango Therapeutics in the S&P 500?

No, Tango Therapeutics is not included in the S&P 500 index

Is Tango Therapeutics in the NASDAQ 100?

No, Tango Therapeutics is not included in the NASDAQ 100 index

Is Tango Therapeutics in the Dow Jones?

No, Tango Therapeutics is not included in the Dow Jones index

When was Tango Therapeutics the previous earnings report?

No data

When does Tango Therapeutics earnings report?

The next expected earnings date for Tango Therapeutics is 08 November 2024